Skip to main content

New Drug Approvals 2011 - Pt. II Vilazodone hydrochloride (ViibrydTM)











ATC code (partial): N06A

On January 21st 2011, the FDA approved Vilazodone hydrochloride for the treatment of major depressive disorder (MDD) (research code: EMD-68843, tradename:Viibryd) (NDA 022567). MDD is a mental disorder believed to arise from abnormal levels of neurotransmitters (primarily serotonin) in the central nervous system. Symptoms are of broad spectrum and typically include depressed mood, fatigue, change of appetite and weight and suicidal thoughts, or attempted suicide. There are already a large number of therapeutics available for the treatment of MDD including the selective serotonin reuptake inhibitors (SSRIs) fluoxetine (ChEMBL41), sertraline (ChEMBL809), paroxetine (CHEMBL569172) and more recently escitalopram (CHEMBL1508). A number of other mechanisms have been explored for treatment of depression, including drugs such as against the serotonin receptor 5HT1A - such as buspirone (research code:BMS-528215, tradename:BuSpar)CHEMBL49) and flesinoxan (clinical trial phase only). Vilazodone however is the first SSRI that also is a partial agonist of 5TH1A (and as such show designed and intended polypharmacology).

Brain function relies on the transmission and regulation of excitatory and inhibitory signals at the synapses of nerve cells. Upon activation, a presynaptic neuron releases neurotransmitters into the synaptic cleft which in turn activate or inhibit the postsynaptic neuron by binding specific receptors. One of the neurotransmitters with excitatory effects is the biogenic amine serotonin (CHEMBL39, CHEBI:28790). After its release from the presynaptic neuron, Serotonin transmits an excitatory signal and is then removed from the synaptic cleft by an uptake mechanism involving the sodium dependent serotonin transporter (SERT) (Ki 0.1nM Uniprot:P31645 Pfam:PF00209). SERT is a member of a very important family of drug targets including the analogous norepinephrine transporter, other pharmacologically important ligands that have related transporters include GABA, dopamine, amino-acids and so forth) Vilazodone is selective for serotonin over the norepinephrine (Ki 56 nM UniProt:P23975) and dopamine transporters (Ki 37 nM UniProt:Q01959). Inhibition of serotonin reuptake with SSRIs leads to increased levels of serotonin in the synaptic cleft and is used in the treatment of MDD to compensate for the lower homeostatic levels of serotonin in MDD patients compared to healthy individuals. The exact mechanism by which this helps MDD patients is not clear but involves long-term desensitization of presynaptic serotonin receptors which are part of a negative feedback loop in the biosynthesis of serotonin. In addition to it's effects as an SSRI, Vilazodone is a partial agonist of the 5HT1A receptor (IC50 2.1 nM, Uniprot:P08908, Pfam:PF00001, ChEMBL:214) (and selective over the related 5-HT1D, 5-HT2A, and 5-HT2C receptors). However the net result of this partial action on serotonergic transmission and its role in Vilazodone’s overall antidepressant effect are unclear. The 5HT1A receptor is a rhodopsin-like G-protein-coupled receptor (GPCR), the largest single family of historically successful drug targets.




Vilazodone (IUPAC: 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide
InChI: 1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
SMILES: NC(=O)c1oc2ccc(cc2c1)N3CCN(CCCCc4c[nH]c5ccc(cc45)C#N)CC3 ChemSpider: 5293518 Chembl:439849) is a synthetic organic molecule with no chiral centers and a molecular weight of 441.5 Da (for the free base) and a calculated LogP of 4.54. With 7 hydrogen bond acceptors and two hydrogen bond donors it is therefore fully compliant with the Lipinski Rule of five. The 7 rotatable bonds make Vilazodone a rather flexible compound. The physical chemistry will be dominated by the basic center in the piperazine ring.

The pharmacology of Vilazodone is largely due to the parent, dosed drug, and due to the long terminal half life of 25 hr (elimination is largely hepatic), steady state plasma levels are reached after about three days. The mean Cmax value is 156 ng/mL, and the mean AUC (0-24 hours) value is 1645 ng·h/mL. Tmax is around 4.5 hr post administration. Vilazodone is widely distributed and approximately 96-99% protein-bound. Vilazodone is extensively metabolized in the liver through CYP and non-CYP pathways with major contributions from CYP3A4 (Uniprot Id: P08684). The non-CYP route is believed to open via liver carboxylesterase (Uniprot Id: P23141). The absolute bioavailability of vilazodone is 72% with food - Vilazodone shows a large food effect, and if taken without food, bioavailability is significantly lower.

Vilazodone is administered orally at a typical dose of 40 mg once daily (equivalent to a daily dose of ~83.6 uM of Vilazodone). At start of therapy, the drug is titrated, starting with 10mg once daily over the course of seven days followed by 20 mg once daily over another 7 days before the full dose of 45 mg per day is administered.

Many drugs of this general class have inherent safety issues, and Vilazodone has safety risks associated with the induction of suicidal thoughts in young adults, adolescents and children. Vilazodone is not approved for the treatment of depressive disorders in children. Viibryd has a boxed warning.

The full prescribing information is found for Vilazodone here.

The license holder is Clinical Data and the product website is http://www.viibryd.com/.

Comments

Popular posts from this blog

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

ChEMBL 29 Released

  We are pleased to announce the release of ChEMBL 29. This version of the database, prepared on 01/07/2021 contains: 2,703,543 compound records 2,105,464 compounds (of which 2,084,724 have mol files) 18,635,916 activities 1,383,553 assays 14,554 targets 81,544 documents Data can be downloaded from the ChEMBL FTP site:   https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_29 .  Please see ChEMBL_29 release notes for full details of all changes in this release: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_29/chembl_29_release_notes.txt New Deposited Datasets EUbOPEN Chemogenomic Library (src_id = 55, ChEMBL Document IDs CHEMBL4649982-CHEMBL4649998): The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project to enable and unlock biology in the open. The aims of the project are to assemble an open access chemogenomic library comprising about 5,000 well annotated compounds covering roughly 1,000 different proteins, to synthesiz

Identifying relevant compounds in patents

  As you may know, patents can be inherently noisy documents which can make it challenging to extract drug discovery information from them, such as the key targets or compounds being claimed. There are many reasons for this, ranging from deliberate obfuscation through to the long and detailed nature of the documents. For example, a typical small molecule patent may contain extensive background information relating to the target biology and disease area, chemical synthesis information, biological assay protocols and pharmacological measurements (which may refer to endogenous substances, existing therapies, reaction intermediates, reagents and reference compounds), in addition to description of the claimed compounds themselves.  The SureChEMBL system extracts this chemical information from patent documents through recognition of chemical names, conversion of images and extraction of attached files, and allows patents to be searched for chemical structures of interest. However, the curren

Julia meets RDKit

Julia is a young programming language that is getting some traction in the scientific community. It is a dynamically typed, memory safe and high performance JIT compiled language that was designed to replace languages such as Matlab, R and Python. We've been keeping an an eye on it for a while but we were missing something... yes, RDKit! Fortunately, Greg very recently added the MinimalLib CFFI interface to the RDKit repertoire. This is nothing else than a C API that makes it very easy to call RDKit from almost any programming language. More information about the MinimalLib is available directly from the source . The existence of this MinimalLib CFFI interface meant that we no longer had an excuse to not give it a go! First, we added a BinaryBuilder recipe for building RDKit's MinimalLib into Julia's Yggdrasil repository (thanks Mosè for reviewing!). The recipe builds and automatically uploads the library to Julia's general package registry. The build currently targe

New Drug Warnings Browser

As mentioned in the announcement post of  ChEMBL 29 , a new Drug Warnings Browser has been created. This is an updated version of the entity browsers in ChEMBL ( Compounds , Targets , Activities , etc). It contains new features that will be tried out with the Drug Warnings and will be applied to the other entities gradually. The new features of the Drug Warnings Browser are described below. More visible buttons to link to other entities This functionality is already available in the old entity browsers, but the button to use it is not easily recognised. In the new version, the buttons are more visible. By using those buttons, users can see the related activities, compounds, drugs, mechanisms of action and drug indications to the drug warnings selected. The page will take users to the corresponding entity browser with the items related to the ones selected, or to all the items in the dataset if the user didn’t select any. Additionally, the process of creating the join query is no